Header Logo

Connection

Kathleen Moore to Piperidines

This is a "connection" page, showing publications Kathleen Moore has written about Piperidines.
Connection Strength

3.111
  1. Niraparib in the treatment of previously treated advanced ovarian, fallopian tubeĀ or primary peritoneal cancer. Future Oncol. 2020 Nov; 16(33):2701-2711.
    View in: PubMed
    Score: 0.696
  2. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019 05; 20(5):636-648.
    View in: PubMed
    Score: 0.631
  3. Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. Cancer Chemother Pharmacol. 2019 04; 83(4):717-726.
    View in: PubMed
    Score: 0.623
  4. The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities. Gynecol Oncol. 2018 04; 149(1):214-220.
    View in: PubMed
    Score: 0.582
  5. The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer. Cancer Chemother Pharmacol. 2018 03; 81(3):497-503.
    View in: PubMed
    Score: 0.580
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.